They contribute to cancer inhibition primarily via the CD8 T cell-mediated CTL response by activation of CD40 in an NO-dependent manner, suggesting that introducing a new agent favoring Tip-DC development may a be feasible option for cancer immunotherapy. This evidence concerns the gene CD8A and cancer.